Organization & Developments: Vascular Biogenics

Parents

2018: VBL Fails Phase 3 Brain Cancer Study, Should Be Avoided_seekingalpha.com
2018: VBL Therapeutics Is Trading Below Cash - VBL Therapeutics (NASDAQ:VBLT)
2020: VBL Therapeutics Announces Enrollment of the First Patients in the Phase 2 Clinical Trial of VB-111 in Metastatic Colorectal Cancer Nasdaq:VBLT
2021: Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump
2021: VBL Therapeutics: A Speculative Play With An Enticing Risk-Reward Profile
2022: Announced that the FDA granted Fast Track designation for ofra-vec with paclitaxel for the treatment of platinum-resistant ovarian cancer.
2022: Less than 2 weeks after failure-induced stock shock, VBL Therapeutics lays off staff
and GT-211, a pro-angiogenic therapy for ischemic diseases.
Biopharmaceutical company, engages in the development and commercialization of treatments for atherosclerosis and cancer.
In addition, it offers vascular targeting system, a platform technology targeting the formation of new blood vessel that enables the delivery of potent compounds to the disease tissue.
It offers CI-201, an anti-inflammatory oral compound for the treatment of atherosclerosis and chronic inflammatory diseases.
The company also provides therapeutic compounds, including GT-111, an anti angiogenic cancer therapy